Literature DB >> 34270097

Radiological assessment of persistent retroperitoneal and lateral pelvic lymph nodes after neoadjuvant therapy for rectal cancer: An analysis of the United States Rectal Cancer Consortium.

Michael K Turgeon1, Adriana C Gamboa1, Jessica M Keilson1, Jeffrey Maniko2, Lillias Maguire2, Katherine Hrebinko3, Jennifer Holder-Murray3, Jason T Wiseman4, Sherif Abdel-Misih4, Saif Hamdan5, Alexander T Hawkins5, Philip Bauer6, Matthew Silviera6, Shishir K Maithel1, Glen C Balch7.   

Abstract

INTRODUCTION: Management of retroperitoneal and lateral pelvic lymph nodes (RLPN) in rectal cancer remains unclear. With total neoadjuvant therapy (TNT), more patients have radiologic complete clinical response (rCR). We sought to evaluate the impact of radiographic persistent RLPN after neoadjuvant therapy on survival.
MATERIALS AND METHODS: Patients with rectal adenocarcinoma with isolated RLPN metastasis, who received neoadjuvant therapy before surgery were included from the United States Rectal Cancer Consortium database. Primary outcomes were recurrence-free survival (RFS) and overall survival (OS).
RESULTS: Of 77 patients, all received neoadjuvant therapy, with 35 (46%) receiving TNT. Posttreatment, 33 (43%) had rCR while 44 (57%) had radiographic persistent RLPN. Median number of radiographic positive RLPN was 1 (IQR 1-2). Receipt of TNT was associated with radiographic RLPN rCR (OR 4.77, 95% CI 1.81-12.60, p < .01). However, there was no difference in RFS and OS between patients who achieved rCR or with persistent RLPN (all p > .05).
CONCLUSIONS: Radiographic persistence of RLPN was not associated with worse survival in well-selected patients and may not be a reliable indicator of pathological response. TNT may be the preferred management strategy to select patients given its association with rCR. Radiographic persistence of RLPN after preoperative therapy should not necessarily preclude surgery.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  neoadjuvant therapy; rectal cancer; retroperitoneal lateral pelvic lymph nodes; total neoadjuvant therapy

Mesh:

Year:  2021        PMID: 34270097      PMCID: PMC8433488          DOI: 10.1002/jso.26600

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   2.885


  36 in total

1.  MR evaluation of normal retroperitoneal and pelvic lymph nodes.

Authors:  Sisa Grubnic; Sarah J Vinnicombe; Andrew R Norman; Janet E Husband
Journal:  Clin Radiol       Date:  2002-03       Impact factor: 2.350

2.  Lateral lymph node metastasis is a major cause of locoregional recurrence in rectal cancer treated with preoperative chemoradiotherapy and curative resection.

Authors:  Tae Hyun Kim; Seung-Yong Jeong; Dong Hyun Choi; Dae Yong Kim; Kyung Hae Jung; Sung Ho Moon; Hee Jin Chang; Seok-Byung Lim; Hyo Seong Choi; Jae-Gahb Park
Journal:  Ann Surg Oncol       Date:  2007-12-05       Impact factor: 5.344

Review 3.  Total neoadjuvant therapy for rectal cancer: An emerging option.

Authors:  Ethan B Ludmir; Manisha Palta; Christopher G Willett; Brian G Czito
Journal:  Cancer       Date:  2017-03-10       Impact factor: 6.860

4.  Diagnostic accuracy of nodal enhancement pattern of rectal cancer at MRI enhanced with ultrasmall superparamagnetic iron oxide: findings in pathologically matched mesorectal lymph nodes.

Authors:  Dow-Mu Koh; Christopher George; Louis Temple; David J Collins; Paul Toomey; Ashraf Raja; Nicholas Bett; Sami Farhat; Janet E Husband; Gina Brown
Journal:  AJR Am J Roentgenol       Date:  2010-06       Impact factor: 3.959

5.  Randomized, controlled trial of lateral node dissection vs. nerve-preserving resection in patients with rectal cancer after preoperative radiotherapy.

Authors:  H Nagawa; T Muto; K Sunouchi; Y Higuchi; G Tsurita; T Watanabe; T Sawada
Journal:  Dis Colon Rectum       Date:  2001-09       Impact factor: 4.585

6.  Lateral Nodal Features on Restaging Magnetic Resonance Imaging Associated With Lateral Local Recurrence in Low Rectal Cancer After Neoadjuvant Chemoradiotherapy or Radiotherapy.

Authors:  Atsushi Ogura; Tsuyoshi Konishi; Geerard L Beets; Chris Cunningham; Julio Garcia-Aguilar; Henrik Iversen; Shigeo Toda; In Kyu Lee; Hong Xiang Lee; Keisuke Uehara; Peter Lee; Hein Putter; Cornelis J H van de Velde; Harm J T Rutten; Jurriaan B Tuynman; Miranda Kusters
Journal:  JAMA Surg       Date:  2019-09-18       Impact factor: 14.766

7.  A comparison between the treatment of low rectal cancer in Japan and the Netherlands, focusing on the patterns of local recurrence.

Authors:  Miranda Kusters; Geerard L Beets; Cornelis J H van de Velde; Regina G H Beets-Tan; Corrie A M Marijnen; Harm J T Rutten; Hein Putter; Yoshihiro Moriya
Journal:  Ann Surg       Date:  2009-02       Impact factor: 12.969

Review 8.  Rectal cancer lateral pelvic sidewall lymph nodes: a review of controversies and management.

Authors:  J S Williamson; A J Quyn; P M Sagar
Journal:  Br J Surg       Date:  2020-08-08       Impact factor: 6.939

9.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer.

Authors:  Toshiaki Watanabe; Michio Itabashi; Yasuhiro Shimada; Shinji Tanaka; Yoshinori Ito; Yoichi Ajioka; Tetsuya Hamaguchi; Ichinosuke Hyodo; Masahiro Igarashi; Hideyuki Ishida; Soichiro Ishihara; Megumi Ishiguro; Yukihide Kanemitsu; Norihiro Kokudo; Kei Muro; Atsushi Ochiai; Masahiko Oguchi; Yasuo Ohkura; Yutaka Saito; Yoshiharu Sakai; Hideki Ueno; Takayuki Yoshino; Narikazu Boku; Takahiro Fujimori; Nobuo Koinuma; Takayuki Morita; Genichi Nishimura; Yuh Sakata; Keiichi Takahashi; Osamu Tsuruta; Toshiharu Yamaguchi; Masahiro Yoshida; Naohiko Yamaguchi; Kenjiro Kotake; Kenichi Sugihara
Journal:  Int J Clin Oncol       Date:  2015-03-18       Impact factor: 3.402

10.  Prognostic impact of residual lateral lymph node metastasis after neoadjuvant (chemo)radiotherapy in patients with advanced low rectal cancer.

Authors:  T Akiyoshi; S Toda; T Tominaga; K Oba; K Tomizawa; Y Hanaoka; T Nagasaki; T Konishi; S Matoba; Y Fukunaga; M Ueno; H Kuroyanagi
Journal:  BJS Open       Date:  2019-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.